19 aprile 2019

18 aprile 2019

TAU BIO-LOGIC Announces Humanization of Picomolar Affinity Monoclonal Antibody Targeting TauC3 Protein for the Treatment of Alzheimer’s Disease and Progressive Supranuclear Palsy

– The humanization of TBL-100 was conducted by LifeArc under a risk sharing agreement with TAU BIO-LOGIC, with terms that would see LifeArc receive a small royalty on future drug sales.  “We are delighted to have contributed to the development of TBL-100, ” said Dr Justin Bryans, head of  LifeArc’s […]